Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Syros Pharmaceuticals, Inc. (SYRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/11/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
07/21/2023 8-K Quarterly results
05/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation, dated May 2023",
"Data Demonstrate Encouraging Clinical Activity in Patients with PDAC Syros will present updated data from the single agent dose escalation portion and the gemcitabine/nab-paclitaxel combination safety lead-in portion of the Phase 1/1b trial. The maximum tolerated dose of SY-5609 as a single-agent was 10 mg using a 7 day on/7 day off dosing schedule. For the doublet, the MTD was 5 mg SY-5609 plus 1000 mg gemcitabine. A MTD was not established using the triplet cohort of SY-5609, gemcitabine and nab-paclitaxel. Each of the single-agent, doublet and the triplet regimens were generally well-tolerated with mostly low-grade events. Encouraging clinical activity was observed at the MTDs with SY-5609 both as a single-agent and in combination . Among the three response evaluable patients with selec..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation, dated January 2023",
"Syros Announces Clinical Updates and 2023 Strategic Priorities"
10/06/2022 8-K Quarterly results
09/16/2022 8-K Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modifications to Rights...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Certificate of Amendment to the Restated Certificate of Incorporation of the Company related to the Share Increase Amendment",
"Certificate of Amendment to the Restated Certificate of Incorporation of the Company related to the Stock Split Amendment",
"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement"
09/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Syros Pharmaceuticals, Inc. 2022 Equity Incentive Plan",
"Syros and Tyme Technologies Announce Stockholder Approval of Merger"
09/02/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ...
07/06/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
01/10/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide presentation dated January 2022",
"Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company"
10/13/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Offer Letter, effective October 12, 2021, between Syros Pharmaceuticals, Inc. and Jason Haas. Filed herewith",
"Form of Nonstatutory Stock Option Agreement for Inducement Awards. Filed herewith"
09/20/2021 8-K Quarterly results
09/10/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/26/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/20/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters identified therein",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Syros Announces Proposed Offering of Common Stock",
"Syros Announces Pricing of $75.6 Million Public Offering of Common Stock"
01/19/2021 8-K Other Events  Interactive Data
01/11/2021 8-K Quarterly results
12/23/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
12/08/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Syros Closes $90.5 Million Strategic Financing"
12/07/2020 8-K Investor presentation, Acquisition/merger/asset purchase announced
Docs: "ASSET PURCHASE AGREEMENT by and between Syros Pharmaceuticals, Inc., as Buyer and Orsenix, LLC, as Seller Dated as of December 4, 2020",
"Form of Warrant to Purchase Common Stock or Pre-Funded Warrants",
"Form of Pre-Funded Warrant",
"Securities Purchase Agreement, by and among Syros Pharmaceuticals, Inc. and the persons party thereto",
"Registration Rights Agreement, by and among Syros Pharmaceuticals, Inc. and the persons party thereto",
"Slide Presentation",
"Syros Presents New Data from Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML",
"Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies"
10/26/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting"
09/09/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/12/2020 8-K Submission of Matters to a Vote of Security Holders
02/13/2020 8-K Quarterly results
01/13/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Slide presentation",
"Syros Announces Strategic Priorities and Expected Milestones"
12/20/2019 8-K Quarterly results
12/18/2019 8-K Entry into a Material Definitive Agreement
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy